- Home
- TNGX vs DSGN Comparison
TNGX vs DSGN Comparison
Compare TNGX & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- DSGN
- Stock Information
- Founded
- TNGX 2014
- DSGN 2017
- Country
- TNGX United States
- DSGN United States
- Employees
- TNGX N/A
- DSGN N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- DSGN Health Care
- Exchange
- TNGX Nasdaq
- DSGN Nasdaq
- Market Cap
- TNGX 248.2M
- DSGN 224.8M
- IPO Year
- TNGX N/A
- DSGN 2021
- Fundamental
- Price
- TNGX $2.49
- DSGN $4.04
- Analyst Decision
- TNGX Strong Buy
- DSGN Hold
- Analyst Count
- TNGX 6
- DSGN 1
- Target Price
- TNGX $12.20
- DSGN $4.00
- AVG Volume (30 Days)
- TNGX 3.5M
- DSGN 91.9K
- Earning Date
- TNGX 05-12-2025
- DSGN 05-07-2025
- Dividend Yield
- TNGX N/A
- DSGN N/A
- EPS Growth
- TNGX N/A
- DSGN N/A
- EPS
- TNGX N/A
- DSGN N/A
- Revenue
- TNGX $40,990,000.00
- DSGN N/A
- Revenue This Year
- TNGX N/A
- DSGN N/A
- Revenue Next Year
- TNGX N/A
- DSGN N/A
- P/E Ratio
- TNGX N/A
- DSGN N/A
- Revenue Growth
- TNGX 10.09
- DSGN N/A
- 52 Week Low
- TNGX $1.03
- DSGN $2.60
- 52 Week High
- TNGX $12.02
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- TNGX 62.72
- DSGN 53.86
- Support Level
- TNGX $1.93
- DSGN $3.67
- Resistance Level
- TNGX $2.67
- DSGN $4.13
- Average True Range (ATR)
- TNGX 0.39
- DSGN 0.30
- MACD
- TNGX 0.07
- DSGN 0.05
- Stochastic Oscillator
- TNGX 55.38
- DSGN 85.78
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.